The signal-to-noise ratio (S/N) was determined for each bone marker using the results of the 83 UK-based patients with duplicate measurements, where the “”signal”" was the Selleck Ferrostatin-1 absolute change of log-transformed values while on therapy, and the buy PF-01367338 “”noise”" was the within-subject biological variability of the measurement (standard deviation of log-transformed measurements on therapy

calculated from the duplicate differences on the subset). Data were analyzed by Eli Lilly and Company using SAS software, version 9.0 (SAS Institute, Inc., Cary, North Carolina, USA), and independently by the first author (AB). Results Patient disposition Of the 868 patients enrolled in the study, two were excluded from all analyses because they had no post-baseline data. Of the 866 evaluable patients at baseline, 758 (87.5%) had at least one evaluable post-baseline bone marker measurement and were included in the analysis: treatment-naïve (n = 181), AR pretreated (n = 209), and inadequate MK-1775 solubility dmso AR responders (n = 368) (Fig. 1). Of these 758 patients, 468 in the three subgroups together continued with a second year of teriparatide treatment, and 443 completed the second year of teriparatide treatment (Fig. 1). Fig. 1 Patient disposition Baseline characteristics The baseline characteristics of the 758 patients

by previous antiresorptive treatment subgroup are given in Table 1. The three subgroups did not differ in age, BMI, or BMD at the hip. Pairwise comparisons showed that LS BMD and height were significantly lower in the inadequate AR responder group than in the other two groups (Table 1). We also observed some variability in weight, height and years since menopause among the subgroups, but these differences are probably a consequence N-acetylglucosamine-1-phosphate transferase of the non-randomized way the patients were assigned to the subgroups. Table 1 Baseline characteristics of the total study population and of each subgroup by previous treatment*   Previous treatment subgroup Characteristic Treatment- naïve AR pretreated Inadequate AR responder Total

N (%) 181 (23.9) 209 (27.6) 368 (48.5) 758 (100.0) Age (years) 70.4 (7.7) 69.3 (7.2) 69.8 (7.5) 69.8 (7.5) Time since menopause (years) 22.7 (9.5) 21.4 (9.0) d 23.4 (9.9) 22.7 (9.6) Weight (kg) 64.4 (11.6)a 62.8 (10.9) 61.3 (10.9) 62.5 (11.1) Height (cm) 158.3 (7.0) a 157.8 (7.1) a 155.7 (7.4) 156.9 (7.3) BMI (kg/m2) 25.7 (4.4) 25.3 (4.4) 25.2 (4.0) 25.4 (4.2) Lumbar spine BMD (g/cm2) 0.751 (0.114) b 0.746 (0.120) 0.728 (0.117) 0.738 (0.118) Lumbar spine BMD (T-Score) −3.01 (0.96) c −3.16 (0.91) d −3.35 (0.95) −3.21 (0.95) Total hip BMD (g/cm2) 0.703 (0.105) 0.703 (0.111) 0.687 (0.110) 0.695 (0.110) Femoral neck BMD (g/cm2) 0.622 (0.108) 0.632 (0.116) 0.620 (0.116) 0.624 (0.114) *for definition of patient subgroups, see the “Participants” sub-heading in the Methods section. Data are presented as mean (standard deviation) with ANOVA test.